1. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma 
Necdet B. Gunsoy, PhD, Sarah M. Cockle, PhD, Steven W. Yancey, MSc, Oliver N. Keene, MSc, Eric S. Bradford, MD, Frank C. Albers, PhD, Ian D. Pavord, FMedSci 
The Journal of Allergy and Clinical Immunology: In Practice 
Volume 6, Issue 3, Pages e4 (May 2018)
DOI: /j.jaip
Copyright © 2017 The Authors Terms and Conditions

2. Figure 1
Illustration of measures to assess the performance of continuation rules using data from randomized controlled trials.
The Journal of Allergy and Clinical Immunology: In Practice 2018 6, e4DOI: ( /j.jaip )
Copyright © 2017 The Authors Terms and Conditions

3. Figure 2
Illustration of criteria used for the assessment of continuation rules, describing thresholds for meeting each criterion, level of evidence for that criterion, and interpretation when criterion not met.
The Journal of Allergy and Clinical Immunology: In Practice 2018 6, e4DOI: ( /j.jaip )
Copyright © 2017 The Authors Terms and Conditions

4. Figure 3
Summary of patients included in the assessment of potential continuation rules.
The Journal of Allergy and Clinical Immunology: In Practice 2018 6, e4DOI: ( /j.jaip )
Copyright © 2017 The Authors Terms and Conditions

5. Figure 4
Results of the assessment of potential continuation rules based on a reduction from baseline blood eosinophils at week 16 after initiation of treatment. The PARR and the RRNC are described in the Methods section. A useful continuation rule should have a PARR of ≤0.8 and an RRNC of ≥0.8. The RRNC decreased as the threshold for reduction in eosinophils increased. All rules met the criteria on PARR and RRNC for MENSA, but not for DREAM.
The Journal of Allergy and Clinical Immunology: In Practice 2018 6, e4DOI: ( /j.jaip )
Copyright © 2017 The Authors Terms and Conditions

6. Figure 5
Results of the assessment of potential continuation rules based on additional measures at week 16 after initiation of treatment. The PARR and the RRNC are described in the Methods section. A useful continuation rule should have a PARR of ≤0.8 and an RRNC of ≥0.8. Criteria for PARR and RRNC were met for “no change or reduction in exacerbations” in MENSA.
The Journal of Allergy and Clinical Immunology: In Practice 2018 6, e4DOI: ( /j.jaip )
Copyright © 2017 The Authors Terms and Conditions